N Pavel Alexandru, Paun Radu, P Matei Valentin
Departmentof Psychiatry, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania.
Departmentof Psychiatry, "Alexandru Obregia" Psychiatric Hospital, Bucharest, Romania.
Psychiatry Clin Psychopharmacol. 2021 Jun 1;31(2):226-232. doi: 10.5152/pcp.2021.21743. eCollection 2021 Jun.
Cannabidiol (CBD) has been used as a pharmacological treatment for psychiatric disorders in many studies, but few of good quality at the moment. Our objective was to assess the effect of CBD in mono/add-on therapy on symptom severity in psychiatric disorders. We performed a systematic review of clinical trials and randomized controlled trials that used CBD as treatment for psychiatric disorders. PRISMA criteria have been used for methodological purposes. Two assessors individually examined the results based on title and abstract, and decided which papers warranted full read. We included studies in English that measured disease severity as primary outcome. Out of 226 studies returned from the search, 9 warranted full read. There were 4 studies using CBD in schizophrenia, 3 studies of substance use disorder and 2 studies of social anxiety. CBD has a good safety profile even in higher doses, but results are inconclusive regarding improvements in disease severity.
在许多研究中，大麻二酚（CBD）已被用作精神疾病的药物治疗方法，但目前高质量的研究较少。我们的目的是评估CBD在单一疗法/联合疗法中对精神疾病症状严重程度的影响。我们对使用CBD治疗精神疾病的临床试验和随机对照试验进行了系统评价。为了方法学目的，采用了PRISMA标准。两名评估人员分别根据标题和摘要检查结果，并决定哪些论文值得全文阅读。我们纳入了以疾病严重程度作为主要结局指标的英文研究。在检索到的226项研究中，有9项值得全文阅读。其中4项研究将CBD用于精神分裂症，3项研究针对物质使用障碍，2项研究针对社交焦虑症。即使在高剂量下，CBD也具有良好的安全性，但关于疾病严重程度改善的结果尚无定论。
